<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03373552</url>
  </required_header>
  <id_info>
    <org_study_id>FattoumaBourguiba</org_study_id>
    <nct_id>NCT03373552</nct_id>
  </id_info>
  <brief_title>Genetic Polymorphism Contributing to the Variability of Clopidogrel Response in Patients With Coronary Artery Disease</brief_title>
  <official_title>Determination of Genetic Polymorphisms Contributing to the Variability of Clopidogrel Response in Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Universitaire Fattouma Bourguiba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Universitaire Fattouma Bourguiba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clopidogrel non-responsiveness is probably multifactorial; several genetic and non genetic&#xD;
      factors may contribute to impaired platelet inhibition by clopidogrel. In this regard, it is&#xD;
      meaningful to determine genetic polymorphisms contributing to the variability of clopidogrel&#xD;
      response in patients with Coronary Artery Therefore, the goal of this study is to determine&#xD;
      the impact of the polymorphisms, affecting CYP2C19, ABCB1, ITGB3 and P2RY12 genes, on the&#xD;
      response to clopidogrel in patients with CAD.Disease (CAD). In fact, the recognition of these&#xD;
      factors might predict the exposure to the risk of thrombosis and cardiovascular death in&#xD;
      these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In an observational study with cross-sectional analysis and prospective data collection, the&#xD;
      investigators recruit patients with:&#xD;
&#xD;
        -  &gt;20 years old&#xD;
&#xD;
        -  An established coronary artery disease defined by an episode of ST-elevation myocardial&#xD;
           infarction, non-ST-elevation acute coronary syndrome or stable angina&#xD;
&#xD;
        -  An exposure to clopidogrel therapy (75 mg per day for at least 10 consecutive days).&#xD;
&#xD;
      The exclusion criteria are:&#xD;
&#xD;
        -  Presence of allergy to clopidogrel&#xD;
&#xD;
        -  Severe hepatic dysfunction, disease or active pathological bleeding (e.g.,&#xD;
           gastrointestinal (GI) bleeding)&#xD;
&#xD;
        -  Use of glycoprotein IIb/IIIa inhibitors or cilostazol&#xD;
&#xD;
        -  inability to give informed consent.&#xD;
&#xD;
      Collected data for patients encompasse baseline characteristics, including age, gender,&#xD;
      obesity (defined as a body mass index ≥30 kg/m2), smoking, medical history, and&#xD;
      coadministered drugs.&#xD;
&#xD;
      The study protocol was approved by the Ethics Committee for Clinical Research at our center&#xD;
      and all subjects gave informed consent for study participation.&#xD;
&#xD;
      Platelet function assay is assessed by the VerifyNow P2Y12 analyzer following manufacturer&#xD;
      instructions (Accumetrics, Inc. San Diego, CA, USA) using venous blood samples collected in&#xD;
      tube containing 3.2% sodium citrate.&#xD;
&#xD;
      Genotyping for CYP2C19, ABCB1, ITGB3 and P2RY12 polymorphism is performed using the&#xD;
      polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) and sequencing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 12, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2029</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Platelet reactivity on clopidogrel</measure>
    <time_frame>at least after 10 days</time_frame>
    <description>Platelet reactivity on clopidogrel is assessed by the VerifyNow P2Y12 assay</description>
  </primary_outcome>
  <other_outcome>
    <measure>Genotyping for genetic polymorphisms</measure>
    <time_frame>an average of 1 month</time_frame>
    <description>Genotyping for genetic polymorphisms is performed using PCR-RFLP and sequencing</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">150</enrollment>
  <condition>Clopidogrel</condition>
  <arm_group>
    <arm_group_label>non responder Group</arm_group_label>
    <description>Platelet function assay:&#xD;
High platelet reactivity: PRU&gt;208</description>
  </arm_group>
  <arm_group>
    <arm_group_label>responder Group</arm_group_label>
    <description>Platelet function assay:&#xD;
PRU&lt;208</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Platelet function assay</intervention_name>
    <description>Platelet function assay</description>
    <arm_group_label>non responder Group</arm_group_label>
    <arm_group_label>responder Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Venous blood samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with coronary artery disease treated by clopidogrel therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient &gt;20 years old&#xD;
&#xD;
          -  Established coronary artery disease defined by an episode of ST-elevation myocardial&#xD;
             infarction, non-ST-elevation acute coronary syndrome or stable angina&#xD;
&#xD;
          -  Exposure to clopidogrel therapy (75 mg per day for at least 10 consecutive days).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of allergy to clopidogrel&#xD;
&#xD;
          -  Severe hepatic dysfunction&#xD;
&#xD;
          -  Disease or active pathological bleeding (e.g., gastrointestinal (GI) bleeding)&#xD;
&#xD;
          -  Use of glycoprotein IIb/IIIa inhibitors or cilostazol&#xD;
&#xD;
          -  inability to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>chouchene saoussen, assistant</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fattouma Bourguiba Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fattouma Bourguiba Hospital</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 7, 2017</study_first_submitted>
  <study_first_submitted_qc>December 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2017</study_first_posted>
  <last_update_submitted>September 12, 2021</last_update_submitted>
  <last_update_submitted_qc>September 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Universitaire Fattouma Bourguiba</investigator_affiliation>
    <investigator_full_name>Chouchene Saoussen</investigator_full_name>
    <investigator_title>Professor Assistant in hematology</investigator_title>
  </responsible_party>
  <keyword>Coronary Artery Disease; Clopidogrel; Polymorphism, genetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

